Xoran starts work on Phase 2 of mobile lung CT NIH grant

ANN ARBOR—Xoran Technologies announced that it had begun work on Phase 2 of their National Institutes of Health mobile lung grant with the goal to confirm the safety and utility of a future point-of-care CT system for the chest, in support of an FDA 510k approved medical device submission.

“It’s hard to overstate how transformative this technology would be for us in the ICU,” said Robert Dickson, M.D., associate professor of pulmonary and critical care medicine, microbiology, and immunology at the University of Michigan. “Every day, we make clinical decisions based on chest X-rays, which are limited in what they can tell us about what is going on in the chest or abdomen. Our patients are often too sick to transport down to radiology, or they have a communicable disease like COVID-19 that we don’t want to spread around the hospital. A bedside scanner would have immediate impact in how we manage our sickest patients.”

In 2021, Xoran Technologies was notified of a grant award from the National Heart, Lung, and Blood Institute, part of the NIH, to support the company’s research and development efforts for lung cone beam computed tomography (CT) imaging. Earlier this year, Xoran announced it had  completed Phase 1 of this grant. Just last month, Xoran submitted its 510k for TRON, an open-bore fluoroscopy CT for full-body point-of-care imaging.

“We greatly appreciate the support from NHLBI as well as a fantastic collaboration with doctors at the University of Michigan,” said William van Kampen, Xoran’s CTO and principal investigator on the project. “This grant enables us to obtain valuable clinical feedback and accelerate our commercialization of this exciting technology and help bring imaging to patients who are in great need.”

This project allows Xoran to optimize a point-of-care solution specifically for lung imaging. The combined Xoran and U of M teams aim to develop a highly deployable CT scanner intended for use in ICU, especially for patients with acute respiratory failure requiring mechanical ventilation.

NHLBI is the global leader in conducting and supporting research in heart, lung, and blood diseases and sleep disorders that advances scientific knowledge, improves public health, and saves lives.

The Weil Institute for Critical Care Research & Innovation is dedicated to pushing the leading edge of research to develop new technologies and novel therapies for the most critically ill and injured patients. Through a unique formula of innovation, integration, and entrepreneurship, their multi-disciplinary teams of health providers, basic scientists, engineers, and data scientists, commercialization coaches, donors and industry partners are taking a boundless approach on re-imagining every aspect of critical care medicine. For more information, visit Weil Institute.

Since 2001, Xoran is the pioneer and medical market leader in low-dose radiation, cone beam CT systems specifically designed for the patient’s point-of-care. Providers around the world rely on its MiniCAT, xCAT, and veterinary CT systems: VetCAT and vTRON, to diagnose and treat patients.

More at www.xorantech.com.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.